With over 0.57 million Oncolytics Biotech Inc. (ONCY) shares trading Tuesday and a closing price of $1.90 on the day, the dollar volume was approximately $1.08 million. The shares have shown a positive half year performance of 94.67% and its price on 01/17/23 gained nearly 15.15%. Currently, there are 58.33M common shares owned by the public and among those 58.26M shares have been available to trade.
Insiders at the company have transacted a total of 7 times over the past 12 months, according to data filed with the U.S. Securities and Exchange Commission (SEC). 7 of these insider trades were purchases, accounting for 90,874 shares. Insider sales of the common stock occurred on 0 occasions, with total insider shares sold totaling 0 shares.
The top 3 mutual fund holders in Oncolytics Biotech Inc. are iShares S&P/TSX Small Cap Index E, Fidelity Nasdaq Composite Index F, and DFA Canadian Small Company Series. iShares S&P/TSX Small Cap Index E owns 69771.0 shares of the company’s stock, all valued at over $0.11 million. The company bought an additional 883.0 shares recently to bring their total holdings to about 0.12% of the shares outstanding. DFA Canadian Small Company Series now owns shares totaling to 0.06% of the shares outstanding.
Shares of Oncolytics Biotech Inc. (NASDAQ: ONCY) opened at $1.69, up $0.04 from a prior closing price of $1.65. However, the script later moved the day high at 1.9000, up 15.15%. The company’s stock has a 5-day price change of 18.01% and 55.74% over the past three months. ONCY shares are trading 16.56% year to date (YTD), with the 12-month market performance up to 23.38% higher. It has a 12-month low price of $0.80 and touched a high of $2.28 over the same period. ONCY has an average intraday trading volume of 283.58K shares. The stock is trading above its simple moving averages at the SMA20, SMA50, and SMA200, as the current price level is off by 12.39%, 15.06%, and 42.29% respectively.
Institutional ownership of Oncolytics Biotech Inc. (NASDAQ: ONCY) shares accounts for 2.50% of the company’s 58.33M shares outstanding. Mutual fund holders own –, while other institutional holders and individual stakeholders account for — and — respectively.
It has a market capitalization of $109.86M and a beta (3y monthly) value of 2.12. The earnings-per-share (ttm) stands at -$0.32. Price movements for the stock have been influenced by the stock’s volatility, which stands at 7.09% over the week and 7.49% over the month.
Analysts forecast that Oncolytics Biotech Inc. (ONCY) will achieve an EPS of -$0.08 for the current quarter, -$0.08 for the next quarter and -$0.33 for 2023. The lowest estimate earnings-per-share for the quarter is -$0.09 while analysts give the company a high EPS estimate of -$0.07. Comparatively, EPS for the current quarter was -$0.07 a year ago. Earnings per share for the fiscal year are expected to increase by 11.90%, and -7.10% over the next financial year.
If you are looking to buy this stock, then you may note that the average analyst recommendation by 5 brokerage firm advisors rate Oncolytics Biotech Inc. (ONCY) as a “Strong Buy” at a consensus score of 1.70. Specifically, 5 Wall Street analysts polled rate the stock as a buy, while 0 of the 5 advise that investors “hold,” and 0 rated it as a “Sell.”
Looking at the support for the ONCY, a number of firms have released research notes about the stock. Maxim Group stated their Buy rating for the stock in a research note on October 06, 2022, with the firm’s price target at $3. H.C. Wainwright coverage for the Oncolytics Biotech Inc. (ONCY) stock in a research note released on February 17, 2021 offered a Buy rating with a price target of $15.